Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway
Empa attenuated cardiomyocyte ferroptosis in DbCM by stabilizing NRF2 through the USP7/NRF2/GPX4 signaling pathway. Targeting the USP7/NRF2/GPX4 pathway may represent a novel therapeutic strategy for attenuating ferroptosis in DbCM, which has clinical significance. <i>Antioxid. Redox Signal.</i> 44, 41-60. <b>Clinical Trials Registration:</b> 2022-SYDWLL-000213.
Authors
- Xiandu Jin
- Ziwei Wang (ORCID: https://orcid.org/0000-0001-6005-0286)
- Hao Wu (ORCID: https://orcid.org/0000-0002-2374-5924)
- Shengzheng Zhang
- Xin Qi (ORCID: https://orcid.org/0000-0002-6040-9567)
- Hanmo Zhang (ORCID: https://orcid.org/0000-0003-0363-2831)
- Junwei Zhang (ORCID: https://orcid.org/0000-0002-3138-9149)
- Wenjun Jia (ORCID: https://orcid.org/0000-0003-0170-6729)
- Zhi Qi (ORCID: https://orcid.org/0000-0002-7819-4736)
- Min Cui
Institutions
- Capital Medical University (CN)
- Nankai University (CN)
- Tianjin People's Hospital (CN)
- Beijing Anzhen Hospital (CN)
- First Affiliated Hospital of Shihezi University Medical College (CN)
Publication Details
- Journal
- Antioxidants and Redox Signaling
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1177/15230864251377765
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59